Findings on golidocitinib with PD-1 antibodies for NSCLC sufferers progressing on anti-PD-1 remedy shall be introduced at ELCC 2025 in Paris this month.Amongst...
Elevation Oncology discontinues EO-3021 for gastric and GEJ cancers after section 1 trial exhibits inadequate efficacy, specializing in advancing EO-1022 as an alternative.Elevation...
Amongst sufferers with HER2-positive early breast most cancers, remedy with Kadcyla (ado-trastuzumab emtansine, T-DM1) has continued to point out sustained enchancment in each...
Gene expression testing helps decide the need of chemotherapy in hormone receptor-positive breast most cancers, optimizing remedy and minimizing pointless toxicity.Breast most cancers...
